<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-72639</identifier>
<setSpec>0300-8932</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Drug-Eluting Stents Versus Bare-Metal Stents in Diabetic Patients With ST-Segment Elevation Acute Myocardial Infarction: A Pooled Analysis of Individual Patient Data From Seven Randomized Trials</dc:title>
<dc:description xml:lang="en">Introduction and objectives. The performance of drug-eluting stents (DES) in high-risk patients with diabetes and acute ST-elevation myocardial infarction (STEMI) who have undergone primary angioplasty has not been previously studied. The objestive was to evaluate the efficacy and safety of DESs in diabetic patients with STEMI. Methods. We performed a pooled analysis of individual patient data from 7 randomized trials that compared DES (ie, sirolimus- or paclitaxel-eluting stents) with bare-metal stent (BMS) in patients with STEMI. The analysis involved 389 patients with diabetes mellitus from a total of 2476 patients. The outcomes of interest were target-lesion revascularization, stent thrombosis, death, and the composite endpoint of death or recurrent myocardial infarction during a follow-up of 12-24 months. Results. Overall, 206 diabetic patients received a DES and 183, a BMS. The risk of target-lesion revascularization was significantly lower in patients treated with a DES compared to those treated with a BMS (hazard ratio [HR] = 0.44; 95% CI, 0.23-0.88; P=.02). There was no significant difference in the risk of stent thrombosis between those treated with a DES or a BMS (HR=0.33; 95% CI, 0.09-1.13; P=.08). Similarly, the risk of the combined endpoint of death or myocardial infarction was not significantly different between patients treated with a DES or a BMS (HR=0.64; 95% CI, 0.36-1.13; P=.12). Conclusions. Compared with BMSs, DES use improved clinical outcomes in diabetic patients undergoing primary angioplasty for STEMI: the need for reintervention was reduced, with no increase in mortality or myocardial infarction. was significantly lower in patients treated with a DES compared to those treated with a BMS (hazard ratio [HR] 0.44, 95% confidence interval [CI] 0.23-0.88; P=.02). There was no significant difference in the risk of stent thrombosis between those treated with a DES or a BMS (HR 0.33, 95% CI 0.09-1.13; P=.08). Similarly, the risk of the combined endpoint of death or myocardial infarction was not significantly different between patients treated with a DES or a BMS (HR 0.64, 95% CI 0.36-1.13; P=.12). Conclusions. Compared with BMSs, DES use improved clinical outcomes in diabetic patients undergoing primary angioplasty for STEMI: the need for reintervention was reduced, with no increase in mortality or myocardial infarction (AU)</dc:description>
<dc:creator>Byrne, Robert A</dc:creator>
<dc:creator>Suttorp, Maarten J</dc:creator>
<dc:creator>Iijima, Raisuke</dc:creator>
<dc:creator>Spaulding, Christian</dc:creator>
<dc:creator>Mehilli, Julinda</dc:creator>
<dc:creator>Kastrati, Adnan</dc:creator>
<dc:creator>Tierala, Ilkka</dc:creator>
<dc:creator>Menichelli, Maurizio</dc:creator>
<dc:creator>Lorenzo, Emilio Di</dc:creator>
<dc:creator>Violini, Roberto</dc:creator>
<dc:creator>Laarman, Gerrit J</dc:creator>
<dc:creator>Schömig, Albert</dc:creator>
<dc:creator>Ndrepepa, Gjin</dc:creator>
<dc:creator>Dibra, Alban</dc:creator>
<dc:creator>Kaiser, Christoph</dc:creator>
<dc:creator>Valgimigli, Marco</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción y objetivos. Los resultados obtenidos con los stents liberadores de fármacos (SLF) en el grupo de pacientes de alto riesgo formado por los pacientes diabéticos con infarto agudo de miocardio con elevación del segmento ST (IAMCEST) tratados con angioplastia primaria no se han estudiado con anterioridad. Nuestro objetivo fue evaluar la eficacia y la seguridad de los SLF en pacientes diabéticos con IAMCEST. Métodos. Llevamos a cabo un análisis combinado de los datos de pacientes individuales de siete ensayos aleatorizados en los que se comparó el empleo de stents liberadores de sirolimus o de paclitaxel (SLF) con el de stents convencionales (SC) en el contexto de un IAMCEST. Se incluyó en este análisis a 389 pacientes con diabetes mellitus de un grupo total de 2.476. Los objetivos del estudio fueron la revascularización de la lesión diana, la trombosis del stent, la muerte y la variable combinada de muerte o infarto de miocardio recurrente durante un periodo de seguimiento de 12-24 meses. Resultados. Hubo 206 pacientes diabéticos tratados con SLF y 183 tratados con SC. El riesgo de que se practicara una revascularización de la lesión diana fue significativamente inferior en los pacientes tratados con SLF en comparación con los pacientes tratados con SC (razón de riesgos [HR] = 0,44; intervalo de confianza [IC] del 95%, 0,23-0,88; p = 0,02). El riesgo de trombosis del stent no presentó diferencias significativas entre los pacientes tratados con SLF y los tratados con SC (HR = 0,33; IC del 95%, 0,09-1,13; p = 0,08). De forma análoga, el riesgo de la variable de valoración combinada formada por la muerte y el infarto de miocardio no presentó diferencias significativas entre los pacientes tratados con SLF y los tratados con SC (HR = 0,64; IC del 95%, 0,36-1,13; p = 0,12). Conclusiones. En comparación con los SC, los SLF mejoran los resultados clínicos en los pacientes diabéticos a los que se practica una angioplastia primaria por un IAMCEST, al reducir la necesidad de reintervención sin incrementar la tasa de mortalidad o infarto de miocardio (AU)</dc:description>
<dc:source>Rev Esp Cardiol;62(4): 354-364, abr. 2009. tab, graf</dc:source>
<dc:identifier>ibc-72639</dc:identifier>
<dc:title xml:lang="es">Stents liberadores de fármacos frente a stents convencionales en pacientes diabéticos con infarto agudo de miocardio con elevación del segmento ST: un análisis combinado de los datos de pacientes individuales de 7 ensayos aleatorizados</dc:title>
<dc:subject>^d29646</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d9395^s22012</dc:subject>
<dc:subject>^d9395^s22067</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d9395^s22016</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d36021^s22067</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d22780</dc:subject>
<dc:subject>^d9396^s22045</dc:subject>
<dc:subject>^d52881^s22074</dc:subject>
<dc:subject>^d14312^s22012</dc:subject>
<dc:subject>^d52881^s22083</dc:subject>
<dc:subject>^d3942^s22016</dc:subject>
<dc:subject>^d30853^s22074</dc:subject>
<dc:subject>^d52881^s22066</dc:subject>
<dc:type>article</dc:type>
<dc:date>200904</dc:date>
</metadata>
</record>
</ibecs-document>
